Japan's Healios Progresses Novel Cell Therapy For ARDS
Activity in Japan's cell and regenerative therapy space continues apace as venture starts trial with lead development asset for acute respiratory distress syndrome.
You may also be interested in...
Big pharma partner takes on prime development responsibility for novel AMD cell therapy as Japanese venture concentrates resources on other in-progress trials.
While the environment for cell and regenerative medicines in Japan is ‘exciting’ and positive, ongoing dialog with policy makers and regulators is needed to ensure a reflection of industry and patient concerns, one CEO says.
A controversial cell therapy for spinal injuries receives coverage under Japan’s national health scheme, amid signs that the pricing of regenerative therapies may come under more scrutiny, while the first CAR-T treatment in the country takes a step closer to market.